Loading
Loading
Research Overview
Combination of FSH and LH activity derived from post-menopausal urine; stimulates follicular development in women and spermatogenesis in men by activating gonadotropin receptors on gonadal tissue.
hMG is a preparation derived from the urine of postmenopausal women containing a mixture of FSH and LH activity. In preclinical reproductive biology research, it has been used to study the combined effects of FSH and LH receptor stimulation on follicular development, granulosa cell biology, and ovarian function in animal model systems. Its combined FSH/LH activity profile makes it useful for research models requiring coordinated gonadotropin stimulation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, human menopausal gonadotropin (hmg) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Human Menopausal Gonadotropin (HMG) research is most relevant to protocols examining:
Assisted reproduction and IVF protocol research
Spermatogenesis induction in hypogonadotrophic hypogonadism studies
Follicular development and FSH/LH combined stimulation research
Gonadotropin receptor biology investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Combination of FSH and LH activity derived from post-menopausal urine; stimulates follicular development in women and spermatogenesis in men by activating gonadotropin receptors on gonadal tissue.
| Parameter | Value |
|---|---|
| Dose range | 75–300 IU/day (per fertility protocol) |
| Schedule | Daily (during stimulation cycles) |
| Route | Subcutaneous, Intramuscular |
| Half-life | ~Hours |
especially females
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.